-
Analyst: Akorn Could Be Sold For As Much As $34 Per Share, But There's Double-Digits Downside If Deal Doesn't Happen
Tuesday, April 11, 2017 - 2:47pm | 385Read More...Last week, Fresenius Kabi, a subsidiary of Fresenius Medical Care AG & Co. (ADR) (NYSE: FMS) said it was looking into the possibility of acquiring Akorn, Inc. (NASDAQ: AKRX). Since the announcement, shares of the latter have spiked more than 30 percent, currently trading close to $32.75. In a...
